Skip to main content
. 2014 Jan 18;4(3):256–266. doi: 10.7150/thno.7781

Figure 2.

Figure 2

(A) Biodistribution of 177Lu-3PRGD2 in U87MG tumor-bearing nude mice at 1 h, 4 h, 24 h, and 72 h after injection (370 kBq per mouse). (B) T/NT ratios of 177Lu-3PRGD2 in U87MG tumor-bearing nude mice at 1 h, 4 h, 24 h, and 72 h after injection (370 kBq per mouse). (C) Comparison of biodistribution of 177Lu-3PRGD2 with/without cold peptide blocking in U87MG tumor-bearing nude mice at 1 h after injection (370 kBq per mouse). (D) Comparison of biodistribution of 177Lu-3PRGD2 with/without Endostar treatment in U87MG tumor-bearing nude mice at 72 h after injection (370 kBq per mouse). Data are expressed as means ± SD (n = 4 per group).